Global Live Vaccines Market Size By Type (Monovalent Live Vaccines, Multivalent Live Vaccines), By Application (Adults, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Live Vaccines Market was valued at USD 18.2 billion in 2023 and is projected to reach USD 29.4 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The rising prevalence of infectious diseases, strong immunogenic potential of live vaccines, and increasing global immunization programs are key factors propelling the market. Live vaccines, containing weakened forms of pathogens, offer long-lasting immunity with fewer doses, making them crucial for combating diseases such as measles, mumps, rubella, tuberculosis, and yellow fever. As emerging and re-emerging infections continue to challenge global healthcare systems, the demand for effective immunization solutions is steadily increasing.

Drivers:

1. Global Vaccination Initiatives:

Government and non-governmental organizations are launching widespread immunization programs targeting preventable diseases. Initiatives by WHO, GAVI, and UNICEF significantly support the distribution and administration of live vaccines in low- and middle-income countries.

2. High Efficacy and Long-Term Protection:

Live vaccines elicit strong cellular and antibody responses, often with lifelong immunity from a single or limited number of doses, which enhances their preference in global vaccination strategies.

3. Increasing Incidence of Infectious Diseases:

Rising outbreaks of diseases such as measles, dengue, and tuberculosis, especially in densely populated and tropical regions, is driving urgent demand for effective vaccine solutions.

Restraints:

1. Cold Chain Dependence:

Live vaccines require stringent cold storage, often between 2°C to 8°C. Inadequate infrastructure in developing regions limits accessibility and viability.

2. Contraindications in Immunocompromised Individuals:

Live attenuated vaccines are not suitable for individuals with compromised immune systems, limiting their use among specific patient populations and reducing their universal applicability.

Opportunity:

1. Technological Advancements in Vaccine Delivery:

Innovations in vaccine storage, microneedle patches, and thermostable formulations are addressing cold chain challenges, paving the way for broader accessibility of live vaccines in remote regions.

2. Expansion in Emerging Markets:

Emerging economies across Asia-Pacific, Latin America, and Africa present high growth potential due to increasing healthcare investments and awareness of disease prevention.

Market by System Type Insights:

Based on system type, the viral-based live vaccines segment dominated in 2023. Live attenuated viral vaccines, such as those for measles, rubella, and varicella, are widely used in national immunization schedules and exhibit strong market performance. The bacterial-based live vaccines segment is also gaining traction, with BCG and typhoid vaccines in high demand in regions with poor sanitation and water infrastructure.

Market by End-use Insights:

By end-use, the pediatric segment accounted for the largest market share in 2023. Children are primary recipients of routine immunizations through national vaccination schedules. The adult segment is projected to grow rapidly due to increasing awareness about adult immunization, travel vaccinations, and pandemic preparedness initiatives.

Market by Regional Insights:

Geographically, Asia-Pacific held the largest market share in 2023, led by expansive immunization programs in India and China, along with rising disease burden. North America is expected to witness robust growth, driven by continuous R&D, strong healthcare infrastructure, and increasing adoption of travel vaccines. Africa and Latin America present untapped opportunities due to ongoing public health challenges and international support for immunization.

Competitive Scenario:

Key players in the Global Live Vaccines Market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Serum Institute of India, Pfizer Inc., Bavarian Nordic, AstraZeneca, Bharat Biotech, Emergent BioSolutions Inc., and Sinovac Biotech Ltd. These companies are actively engaged in product development, strategic collaborations, and geographical expansions to strengthen their market presence.

Key Developments:

In 2023, Merck received expanded FDA approval for its live MMR vaccine to cover additional age groups.

Serum Institute of India increased production capacity of its live oral rotavirus vaccine to meet global demand through UNICEF procurement.

In 2024, Pfizer initiated clinical trials for a new intranasal live attenuated influenza vaccine targeting pandemic preparedness.

Scope of Work – Global Live Vaccines Market

Key Market Developments:

2023: Merck expands MMR vaccine indication across multiple age groups.

2024: Pfizer launches intranasal flu vaccine in clinical trials.

2023: Serum Institute scales rotavirus vaccine production for UNICEF supply.

FAQs:

1) What is the current market size of the Global Live Vaccines Market?

The Global Live Vaccines Market was valued at USD 18.2 billion in 2023.

2) What is the major growth driver of the Global Live Vaccines Market?

Key drivers include rising immunization initiatives, high efficacy of live vaccines, and increasing infectious disease prevalence.

3) Which is the largest region during the forecast period in the Global Live Vaccines Market?

Asia-Pacific is the largest region due to expansive immunization coverage and high disease burden.

4) Which segment accounted for the largest market share in Global Live Vaccines Market?

The pediatric segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Live Vaccines Market?

Major players include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Serum Institute of India, Pfizer, and AstraZeneca.